Atlas Trials

Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer

Clinical trial NCT02500121 · COMPLETED

Trial details

NCT number
NCT02500121
Sponsor
Matthew Galsky
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Urothelial CarcinomaBladder Cancer
Start date
2015-11-11
Primary completion
2019-07-01
Enrollment
108

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.